BioMarin-Amicus deal pays CDO Castelli (FOLD) $14.50 per share
Rhea-AI Filing Summary
AMICUS THERAPEUTICS, INC. Chief Development Officer Jeff Castelli reported disposing of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. In the transaction, he disposed of 427,089 shares of Common Stock at $14.50 per share, including 318,417 shares of Common Stock and 108,672 restricted stock units that vested in full at closing.
Several fully vested stock option awards were also cancelled and converted into the right to receive cash equal to $14.50 per share minus each option’s exercise price, multiplied by the option share count. Following these dispositions, the filing shows no remaining Common Stock or stock options held directly by Castelli.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 427,089 shares
Net Sell
7 txns
Insider
Castelli Jeff
Role
Chief Development Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 82,644 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 107,575 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 108,266 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 125,462 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 99,073 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 150,517 | $0.00 | $0.00 |
| Disposition | Common Stock | 427,089 | $14.50 | $6.19M |
Holdings After Transaction:
Stock Options (right to buy) — 0 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 318,417 shares of Common Stock and 108,672 restricted stock units (which vested in full in connection with consummation of the Merger).
- F2. In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
- F3. Each Option was fully vested.
- F4. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common Stock disposed: 427,089 shares
Merger share price: $14.50 per share
Restricted stock units vested: 108,672 units
+4 more
7 metrics
Common Stock disposed
427,089 shares
Disposed to issuer at $14.50 per share in merger
Merger share price
$14.50 per share
Price used for Common Stock and option cash-out
Restricted stock units vested
108,672 units
Vested in full upon consummation of the merger
Option block 1 shares
150,517 shares
Stock options at $9.41 exercise price, cancelled for cash
Option block 2 shares
99,073 shares
Stock options at $14.24 exercise price, cancelled for cash
Option block 3 shares
125,462 shares
Stock options at $11.93 exercise price, cancelled for cash
Post-transaction holdings
0 shares / 0 options
Total Common Stock and options after merger-related dispositions
Key Terms
restricted stock units, stock option, disposition to issuer, Merger, +1 more
5 terms
restricted stock units financial
"which included 318,417 shares of Common Stock and 108,672 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"In connection with consummation of the Merger, each reported stock option ("Option") was cancelled"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
disposition to issuer financial
"transaction_code_description: "Disposition to issuer" for each reported transaction"
Merger financial
"disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
exercise price financial
"equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Jeff Castelli report in this Amicus (FOLD) Form 4 filing?
Jeff Castelli reported disposing of his Amicus equity in connection with the BioMarin acquisition. He surrendered 427,089 Common Stock shares and multiple stock option awards, all converted into cash rights based on a $14.50 per share merger price.
What happened to Jeff Castelli’s Amicus (FOLD) stock options in the BioMarin merger?
Each reported stock option was cancelled at closing and converted into a cash right. The payment equals $14.50 per share minus the option’s exercise price, multiplied by the total number of shares subject to that option award.
Were Jeff Castelli’s Amicus (FOLD) stock options vested before the merger?
Yes. Footnotes state each option was fully vested. Some options were already fully vested, and others vested in full in connection with consummation of the merger, before being cancelled and converted into cash-based rights.